Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology
Jun 26, 2017
PDF 284.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma
Jun 16, 2017
PDF 331.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma
Jun 15, 2017
PDF 285.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma
Jun 14, 2017
PDF 285.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress
Jun 13, 2017
PDF 286.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma
Jun 8, 2017
PDF 284.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 2017 Jefferies Global Healthcare Conference
Jun 6, 2017
PDF 278.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology
Jun 5, 2017
PDF 328.3 KB Add to Briefcase
View Summary TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology
Jun 3, 2017
PDF 288.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
Jun 2, 2017
PDF 285.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial
May 23, 2017
PDF 282.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma
May 19, 2017
PDF 284.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress
May 18, 2017
PDF 284.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
May 17, 2017
PDF 285.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results
May 5, 2017
PDF 291.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update
May 3, 2017
PDF 278.8 KB Add to Briefcase
View Summary TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting
Apr 28, 2017
PDF 285.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting
Apr 24, 2017
PDF 283.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
Apr 20, 2017
PDF 286.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company's Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting
Apr 4, 2017
PDF 284.7 KB Add to Briefcase
Showing 21-40 of 214 Page: 1 2 3 4 5 6 ... 11  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase